Referral of Early-Stage NSCLC to Multidisciplinary Teams

EP: 1.Treatment Approaches for Early-Stage Lung Cancer

EP: 2.Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 3.Neoadjuvant/Perioperative Immunotherapy in NSCLC

Now Viewing

EP: 4.Referral of Early-Stage NSCLC to Multidisciplinary Teams

EP: 5.Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 6.Updates in CheckMate-816 From ESMO 2023

EP: 7.AEGEAN Trial: Perioperative Approach in NSCLC

EP: 8.Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 9.CheckMate-77T Trial Results From ESMO 2023

EP: 10.Treatment Decision Making by Stage for Resectable NSCLC

EP: 11.The Emerging Role of ctDNA in NSCLC Management

EP: 12.Addressing Gaps in Care for Non-Small Cell Lung Cancer

This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss how patients with early-stage lung cancer are referred to multidisciplinary teams at their respective institutions. At MD Anderson Cancer Center, patients can be referred directly from primary care physicians/community physicians to a multidisciplinary clinic where they see thoracic medical oncology, surgery, and radiation specialists on the same day. Invasive mediastinal staging is often set up in advance by interventional pulmonologists. Another path is through general oncology, where staging and molecular profiling are completed before referral to the multidisciplinary team.

The determination of resectability is crucial, especially with the availability of preoperative therapies. Patients typically undergo a CT scan, biopsy, mediastinal staging, PET scan, brain MRI, and chest CT with intravenous contrast to assess technical and medical resectability. In phase 3 trials of neoadjuvant and perioperative strategies, patients were evaluated by thoracic surgeons to ensure medically and technically resectable tumors prior to enrollment. These trials did not aim to convert unresectable tumors to resectable. The definition of resectability is evolving, with some trials including stage IIIA, IIIB, and multistation N2 disease, but ultimately depends on the surgeon’s assessment and the patient’s fitness for surgery.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.